• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用杜氏利什曼原虫的FML抗原对瑞士白化小鼠进行实验性内脏利什曼病疫苗接种。

Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani.

作者信息

Santos W R, Paraguai de Souza E, Palatnik M, Palatnik de Sousa C B

机构信息

Instituto de Microbiologia, Prof. Paulo de Góes, Universidade Federal do Rio de Janeiro (UFRJ), CCS, Cidade Universitária, Brazil.

出版信息

Vaccine. 1999 Jun 4;17(20-21):2554-61. doi: 10.1016/s0264-410x(99)00058-4.

DOI:10.1016/s0264-410x(99)00058-4
PMID:10418902
Abstract

The FML antigen of Leishmania donovani in combination with saponin, aluminum hydroxide (Al(OH)3) and Freund's incomplete adjuvant (FIA) was used in vaccines tested in an outbred murine model of visceral leishmaniasis, either through intraperitoneal or subcutaneous routes. The humoral response was significantly higher in the groups treated with FML + saponin or FML + Al(OH)3 than in controls, both before and after the infection. Animals immunized by the i.p. route developed higher antibody titres. A significant and specific reduction of parasitic load in relation to saline (85%, p < 0.01) and saponin (p < 0.025) controls, was seen in animals treated with FML + saponin by the i.p. Coincidentally with this reduction, an increase in antibodies of the IgG2a subtype was detected only in animals treated with FML + saponin i.p. A reduction of 88% in parasitic load was achieved by the combination of FML + Al(OH)3 (s.c.), but the Al(OH)3 treatment itself accounted for 68% of this protection. In our conditions, vaccination with FML + saponin i.p. was superior to other treatments and had no toxic effect due to saponin.

摘要

杜氏利什曼原虫的FML抗原与皂苷、氢氧化铝(Al(OH)3)和弗氏不完全佐剂(FIA)联合,通过腹腔内或皮下途径,用于在内脏利什曼病远交系小鼠模型中测试的疫苗。在感染前后,用FML +皂苷或FML + Al(OH)3处理的组的体液反应均显著高于对照组。通过腹腔内途径免疫的动物产生了更高的抗体滴度。与盐水(85%,p < 0.01)和皂苷(p < 0.025)对照组相比,腹腔内注射FML +皂苷处理的动物的寄生虫负荷显著且特异性降低。与此降低同时,仅在腹腔内注射FML +皂苷处理的动物中检测到IgG2a亚型抗体增加。FML + Al(OH)3(皮下)联合使用使寄生虫负荷降低了88%,但Al(OH)3处理本身占这种保护作用的68%。在我们的条件下,腹腔内注射FML +皂苷进行疫苗接种优于其他处理,并且皂苷没有毒性作用。

相似文献

1
Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani.用杜氏利什曼原虫的FML抗原对瑞士白化小鼠进行实验性内脏利什曼病疫苗接种。
Vaccine. 1999 Jun 4;17(20-21):2554-61. doi: 10.1016/s0264-410x(99)00058-4.
2
Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis.用于抗小鼠内脏利什曼病的FML疫苗制剂中的皂苷、白细胞介素12和卡介苗佐剂。
Vaccine. 2002 Nov 22;21(1-2):30-43. doi: 10.1016/s0264-410x(02)00444-9.
3
Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani.植物皂苷和佐剂的溶血活性。地中海佩里安德拉皂苷对杜氏利什曼原虫FML抗原体液反应的影响。
Vaccine. 1997 Jun;15(9):1024-9. doi: 10.1016/s0264-410x(96)00292-7.
4
Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.皂树混合酰化和去酰化皂苷作为抗内脏利什曼病FML疫苗的佐剂
Vaccine. 2006 May 1;24(18):3909-20. doi: 10.1016/j.vaccine.2006.02.034. Epub 2006 Mar 2.
5
Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine.
Vaccine. 2003 Dec 1;21(32):4668-76. doi: 10.1016/s0264-410x(03)00527-9.
6
Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani.
Vaccine. 2001 Apr 30;19(23-24):3104-15. doi: 10.1016/s0264-410x(01)00031-7.
7
The FML (Fucose Mannose Ligand) of Leishmania donovani. a new tool in diagnosis, prognosis, transfusional control and vaccination against human kala-azar.
Rev Soc Bras Med Trop. 1996 Mar-Apr;29(2):153-63. doi: 10.1590/s0037-86821996000200008.
8
Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis.评价不同佐剂与致死量感染杜氏利什曼原虫抗原联合应用对实验内脏利什曼病的免疫原性和保护效果。
Med Microbiol Immunol. 2015 Aug;204(4):539-50. doi: 10.1007/s00430-014-0367-9. Epub 2014 Nov 29.
9
Protective vaccination against murine visceral leishmaniasis using aldehyde-containing Quillaja saponaria sapogenins.使用含醛的皂树皂苷元对小鼠内脏利什曼病进行保护性疫苗接种。
Vaccine. 2004 Jun 23;22(19):2470-9. doi: 10.1016/j.vaccine.2004.01.072.
10
Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN).在巴西(北里奥格兰德州圣贡萨洛-杜阿马兰特)的一个流行地区,使用FML-皂树素疫苗对犬类黑热病进行长期保护。
Vaccine. 2002 Sep 10;20(27-28):3277-84. doi: 10.1016/s0264-410x(02)00294-3.

引用本文的文献

1
Immunogenicity and protective efficacy of tuzin protein as a vaccine candidate in -infected BALB/c mice.图津蛋白作为候选疫苗在感染的BALB/c小鼠中的免疫原性和保护效力。
Front Immunol. 2024 Jan 11;14:1294397. doi: 10.3389/fimmu.2023.1294397. eCollection 2023.
2
Vaccination in Leishmaniasis: A Review Article.《利什曼病疫苗接种:综述文章》。
Iran Biomed J. 2022 Jan 1;26(1):1-35. doi: 10.52547/ibj.26.1.35.
3
Development of the Antileishmanial Vaccine.抗利什曼原虫疫苗的研制。
Methods Mol Biol. 2022;2410:433-461. doi: 10.1007/978-1-0716-1884-4_23.
4
Anti-Leishmanial Vaccines: Assumptions, Approaches, and Annulments.抗利什曼原虫疫苗:假设、方法与废止
Vaccines (Basel). 2019 Oct 18;7(4):156. doi: 10.3390/vaccines7040156.
5
Nucleoside Hydrolase (NH36) Domains Induce T-Cell Cytokine Responses in Human Visceral Leishmaniasis.核苷水解酶(NH36)结构域在人类内脏利什曼病中诱导T细胞细胞因子反应。
Front Immunol. 2017 Mar 7;8:227. doi: 10.3389/fimmu.2017.00227. eCollection 2017.
6
A Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the Nucleoside Hydrolase (NH36) Optimizes Cross-Protection against Infection.一种包含核苷水解酶(NH36)的CD4 +和CD8 + T细胞表位的嵌合体可优化针对感染的交叉保护作用。
Front Immunol. 2017 Feb 23;8:100. doi: 10.3389/fimmu.2017.00100. eCollection 2017.
7
Multicomponent LBSap vaccine displays immunological and parasitological profiles similar to those of Leish-Tec® and Leishmune® vaccines against visceral leishmaniasis.多组分LBSap疫苗展现出与Leish-Tec®和Leishmune®疫苗相似的免疫和寄生虫学特征,可用于治疗内脏利什曼病。
Parasit Vectors. 2016 Aug 30;9(1):472. doi: 10.1186/s13071-016-1752-6.
8
Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic properties.具有免疫原性的工程化酵母表达杜氏利什曼原虫核苷水解酶的表达与纯化
Hum Vaccin Immunother. 2016 Jul 2;12(7):1707-20. doi: 10.1080/21645515.2016.1139254. Epub 2016 Feb 2.
9
From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.从鼠到人:候选利什曼病疫苗 LEISH-F3+GLA-SE 的安全性、免疫原性和疗效。
Clin Transl Immunology. 2015 Apr 10;4(4):e35. doi: 10.1038/cti.2015.6. eCollection 2015 Apr.
10
Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches.内脏利什曼病:通过经典和分子方法在疫苗开发方面的进展。
Front Immunol. 2014 Aug 22;5:380. doi: 10.3389/fimmu.2014.00380. eCollection 2014.